Advertisement

Heart Failure Controversies

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

The prevalence of heart failure (HF) rises from 2% to 3% at age 65 to more than 50% in persons older than age 80. Many of these patients have HFPEF. The condition is not uncommon in elderly women, most of whom have hypertension, diabetes mellitus, or both and often coronary heart disease (CHD). However, CHD more commonly causes systolic heart failure (SHF). Atrial fibrillation is common in the elderly, and ventricular rates even when not very rapid (120-140) may precipitate HF with a preserved ejection fraction (EF).

Keywords

Diastolic Dysfunction Heart Failure Patient Angiotensin Receptor Blocker Constrictive Pericarditis Systolic Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mauer MS, Spevack D, Burkhoff D, Kronzon I. Diastolic dysfunction: Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 2004;44:1543–1549.CrossRefGoogle Scholar
  2. 2.
    Oh, JK, Hatle L, Tajik AJ, et al. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006;47:500–506.PubMedCrossRefGoogle Scholar
  3. 3.
    ACC/AH A guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. J Am Coll Cardiol 2001;8:2101.Google Scholar
  4. 4.
    Vasan RS, Levy D. Defining diastolic heart failure. A call for standardized diagnostic criteria. Circulation 2000;101:2118.PubMedGoogle Scholar
  5. 5.
    Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387–1393.PubMedCrossRefGoogle Scholar
  6. 6.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005guideline update for the diagnosis and management of chronic heart failure in the adult—summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1116–1143.CrossRefGoogle Scholar
  7. 7.
    Little WC, Cheng CP. Diastolic dysfunction. Cardiol Rev 1998;6:231.PubMedCrossRefGoogle Scholar
  8. 8.
    Meier-Ewert HK, Gaasch WH. What is diastolic heart failure and how do we treat it? ACC Curr J Rev Nov/Dec:52, 2001.Google Scholar
  9. 9.
    Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277.PubMedCrossRefGoogle Scholar
  10. 10.
    Khan M Gabriel. Cardiomyopathy. In: Heart Disease, Diagnosis and Therapy. Totowa, NJ, HumanaPress, 2005, pp. 443–470.Google Scholar
  11. 11.
    Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.PubMedCrossRefGoogle Scholar
  12. 12.
    Eichhorn EJ, Gheorghiade M. Digoxin—new perspective on an old drug. N Engl J Med 2002;47:1394.CrossRefGoogle Scholar
  13. 13.
    Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777–781.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.PubMedCrossRefGoogle Scholar
  15. 15.
    McMurray JJV, Ostergren J, Swedberg K, Granger CB. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767–771.PubMedCrossRefGoogle Scholar
  16. 16.
    Pitt B, Zannad F, Remme WJ, et al. for the Randomized Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341: 709.PubMedCrossRefGoogle Scholar
  17. 17.
    Pitt B, Remme W, Zannad F, et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.PubMedCrossRefGoogle Scholar
  19. 19.
    Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161.PubMedCrossRefGoogle Scholar
  20. 20.
    Jourdain P, Funck F, Gueffet P, et al. Benefits of BNP plasma levels for optimizing therapy: The Systolic Heart Failure Treatment supported by BNP multicenter randomised trial (STARS-BNP). (abstr) J Am Coll Cardiol 2005;45(Suppl A):3A.Google Scholar
  21. 21.
    Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 2003; 42:1793–1800.PubMedCrossRefGoogle Scholar
  22. 22.
    Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 2005;111:1487–1491.PubMedCrossRefGoogle Scholar
  23. 23.
    Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005;293:1900–1905.PubMedCrossRefGoogle Scholar
  24. 24.
    Scirica BM, Morrow DA, Cannon CP, et al, for the PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol 2006;47:2326–2331.PubMedCrossRefGoogle Scholar
  25. 25.
    Sola S, Mir MQS, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332–337.PubMedCrossRefGoogle Scholar
  26. 26.
    Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006;47:342–344.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation 2006; 114:2572–2574.PubMedCrossRefGoogle Scholar
  2. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556–2564.PubMedCrossRefGoogle Scholar
  3. Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006;47:342–344.PubMedCrossRefGoogle Scholar
  4. Scirica BM, Morrow DA, Cannon CP, et al, for the PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol 2006;47:2326–2331.PubMedCrossRefGoogle Scholar
  5. Stevens LA, Coresh J, Greene T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.PubMedCrossRefGoogle Scholar
  6. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations